IBIO-600
Obesity and Cardiometabolic Disease
IND-EnablingActive
Key Facts
About iBio
iBio's mission is to develop next-generation antibody therapies for obesity and cardiometabolic disorders, targeting validated but historically difficult-to-drug pathways like GPCRs. Its core achievement is the creation of an integrated AI and wet-lab discovery platform designed to accelerate development and reduce late-stage failure risks. The company's strategy focuses on advancing a pipeline of fully human antibodies with improved profiles—such as muscle preservation and less frequent dosing—through clinical validation, while exploring strategic partnerships to expand its impact.
View full company profileTherapeutic Areas
Other Obesity and Cardiometabolic Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| IBIO-610 | iBio | IND-Enabling |
| Myostatin x Activin A Bispecific | iBio | Optimization |